medigraphic.com

2012, Número 4

<< Anterior Siguiente >>

Rev Latinoam Psiquiatría 2012; 11 (4)


Impacto del tabaquismo en el trastorno bipolar

Díaz-Jiménez R, García-Portilla GP, García-Álvarez L, Bobes GJ

Idioma: Español
Referencias bibliográficas: 89
Paginas: 141-155
Archivo PDF: 505.84 Kb.


RESUMEN

Antecedentes: el tabaquismo es un problema de salud pública en todo el mundo, la prevalencia del consumo de tabaco en los pacientes con trastorno bipolar es 2 a 4 veces mayor que en la población general.
Material y método: estudio retrospectivo efectuado con base en la búsqueda en la base de datos publicados de PubMed. Los términos de búsqueda fueron: fumar y trastorno bipolar. Se obtuvieron 18 artículos y además se buscó en la lista de referencia de los artículos seleccionados para las referencias adicionales pertinentes.
Resultados: existen altas tasas de prevalencia de consumo de tabaco en la población con trastorno bipolar, lo que implica consecuencias pronósticas importantes al asociarse con consumo más intenso, mayores riesgos suicidas y comorbilidades somáticas y psiquiátricas (trastorno por consumo de otras sustancias) y mayores dificultades para el abandono.
Conclusiones: para la población general existe una serie de tratamientos efectivos para dejar de fumar de la que también podrían beneficiarse los pacientes con trastorno bipolar. Se necesitan estudios controlados específicos para esta población.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Hirschfeld RM, Calabrese JR, Weissman MM et al. Screening for bipolar disorder in the community J Clin Psychiatry 2003; 64:53-59.

  2. Lising-Enriquez K, George TP. Treatment of comorbid tobacco use in people with serious mental illness. J Psychiatry Neurosci 2009;34:E1-E2.

  3. Lasser K, Boyd JW, Woolhandler S, et al. Smoking and mental illness: a population-based prevalence study. JAMA 2000; 284:2606-2610.

  4. Gonzalez–Pinto A, Gutierrez M, Ezcurra J, et al. Tobacco smoking and bipolar disorder. J Clin Psychiatry 1998;59:225- 228.

  5. Goldstein BI, Birmaher B, Axelson DA, et al. Significance of cigarette smoking among youths with bipolar disorder. Am J Addict 2008;17:364-371.

  6. Vanable PA, Carey MP, Carey KB, et al. Smoking among psychiatric outpatients: relationship to substance use, diagnosis, and illness severity. Psychol Addict Behav 2003;17:259-265

  7. Waxmonsky JA, Thomas MR, Miklowitz DE, et al. Gen Hosp Psychiatry 2005;27:321-328

  8. García-Portilla MP, Sáiz PA, Benabarre A, et al. Impact of substance use on the physical health of patients with bipolar disorder. Acta Psychiatr Scand 2010; 121:437-445.

  9. Diaz FJ, James D, Botts S, et al. Tobacco smoking behaviors in bipolar disorder: a comparison of the general population, schizophrenia, and major depression. Bipolar Disord 2009;11:154-165.

  10. Ostacher MJ, Nierenberg AA, Perlis RH, et al. The relationship between smoking and suicidal behavior, comorbidity, and course of illness in bipolar disorder. J Clin Psychiatry 2006;67:1907-1911.

  11. Oquendo MA, Bongiovi-García ME, Galfalvy HC et al. Agression and substance abuse in bipolar disorder. Bipolar Disord. 2006; 8:496-502.

  12. Vieta E, Martínez A. Abordaje actual de la manía aguda. Primera edición. España: Grupo Saned; 2011.

  13. McIntyre RS, Konarski JZ, Soczynska JK et al. Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization. Psychiatr Serv. 2006; 57:1140-1144.

  14. Barr RS, Culhane MA, Jubelt LE et al. The effects of transdermal nicotine on cognition in non-smokers with schizophrenia and non psychiatric controls. Neuropsychopharmacol. 2008; 33:480-490.

  15. Gurrea A, Pinett MC. Tabaco y patología afectiva. Adicciones 2004; 16:155 – 175.

  16. Betnowitz NL. Pharmacology of nicotine: Addiction, smokinginduced disease, and therapeutics. Annu Rev Pharmacol Toxicol. 2009; 49, 57-71.

  17. Itkin O, Nemets B, Eianat H. Smoking habits in bipolar and schizophrenic outpatients in southern Israel. J Clin Psychiatry. 2001; 62:269-72

  18. Del Bello MP, Hanseman D, Adler CM et al. Twelve-month outcome of adolescents with bipolar disorder following first Hospitalization for a manic or mixed episode. Am J Psychiatry. 2007; 164: 582–590.

  19. Nolen WA, Luckenbaugh DA, Altshuler LL et al. Correlates of 1-year prospective outcome in bipolar disorder: results from the Stanley Foundation Bipolar Network. Am J Psychiatry. 2004; 161: 1447-1454.

  20. Berk M, Ng F, Wang WV et al. Going up in smoke: Tobacco smoking is associated with worse treatment outcomes in mania. J Affect Disord. 2008; 110: 126-134.

  21. McClave AK, McKnight-Eily LR, Davis SP, Dube SR. Smoking characteristics of adults with selected lifetime mental illnesses: results from the 2007 National Health Interview Survey. Am J Public Health. 2010; 100: 2464-2472.

  22. Heffner JL, Del Bello MP, Fleck DE et al. Cigarette smoking among individuals with bipolar disorder: association with ages-at-onset of alcohol and marijuana use. Bipolar Disord. 2008; 10: 838–845.

  23. Kilbourne AM, Morden NE, Austin K et al. Excess heart disease-related mortality in a national study of patients with mental disorders: identifying modifiable risk factors. Gen Hosp Psychiatry. 2009; 31: 555–563.

  24. Heffner JL, Strawn JR, Del Bello MP et al. The co-ocurrence of cigarette smoking and bipolar disorder: phenomenology and treatment considerations. Bipolar Disord. 2011: 13: 439-453.

  25. Willens TE, Biederman J, Milberger S et al. Is bipolar disorder a risk for cigarette smoking in ADHD youth? Am J Addict. 2000; 9 (3): 187-195

  26. Picciotto M, Brunzell D, Caldarone B. Effect of nicotine and nicotine receptors on anxiety and depression. Neuro Report. 2002; 13(9): 1097-1106.

  27. Breslau N, Kilbey MM, Andreski P. Nicotine withdrawal symptoms and psychiatric disorders: findings from an epidemiologic study of young adults. Am J Psychiatry 1992;149: 464-469.

  28. Markou A, Kosten TR, Koob GF. Neurobiological similarities in depression and drug dependence: a self-medication hypothesis. Neuropsychopharmacol. 1998; 18: 135-174.

  29. Boden JM, Fergusson DM, Horwood LJ. Cigarette smoking and depression: tests of causal linkages using a longitudinal birth cohort. Br J Psychiatry 2010; 196: 440–446.

  30. McKenzie M, Olsson CA, Jorm AF et al. Association of adolescent symptoms of depression and anxiety with daily smoking and nicotine dependence in young adulthood: findings from a 10-year longitudinal study. Addiction 2010; 105: 1652–1659.

  31. Breslau N, Peterson EL, Schultz LR et al. Major depression and stages of smoking: a longitudinal investigation. Arch Gen Psychiatry 1998; 55:161–166.

  32. McEachin RC, Saccone NL, Saccone SF et al. Modeling complex genetic and environmental influences on comorbid bipolar disorder with tobacco use disorder. BMC Med Genet 2010; 11: 14.

  33. Strawn JR, Ekhator NN, Anthenelli RM et al. Intra- and inter-individual relationships between central and peripheral serotonergic activity in humans: a serial cerebrospinal fluid sampling study. Life Sci, 2002; 71: 1219–1225.

  34. Arinami T, Ishiguro H, Onaivi E. Polymorphisms in genes involved in neurotransmission in relation to smoking. Eu J Pharmacol. 2000; 410:215-26.

  35. Cerullo MA, Adler CM, Del bello MP, Strakowski SM. The functional neuroanatomy of bipolar disorder. Int Rev Psychiatry. 2009; 21: 314–322.

  36. Gamberino WC, Gold MS. Neurobiology of tobacco smoking and other addictive disorders. Psychiatr Clin North Am. 1999 Jun; 22: 301–312

  37. Brody AL, Mandelkern MA, Jarvik ME et al. Differences between smokers and non smokers in regional gray matter volumes and densities. Biol Psychiatry. 2004; 55:77–84.

  38. Soares JC, Kochunov P, Monkul ES et al. Structural brain changes in bipolar disorder using deformation field morphometry. Neuroreport 2005; 16: 541–544.

  39. Saccone KA, George TP, Head CA et al. Adverse childhood experiences, smoking and mental illness in adulthood: a preliminary study. Ann Clin Psychiatry. 2007; 19: 89–97.

  40. Jackson KM, Sher KJ, Cooper ML, Wood PK. Adolescent alcohol and tobacco use: onset, persistence, and trajectories of use across two samples. Addiction 2002; 97:517–531.

  41. Patton GC, Coffey C, Carlin JB et al. Reverse gateways? Frequent cannabis use as a predictor of tobacco initiation and nicotine dependence. Addiction 2005; 100: 1518–1525.

  42. López-Ortiz C, Roncero C, Miquel L, Casas M. Smoking in affective psychosis: Review about nicotine use in bipolar and schizoaffective disorders. Adicciones. 2011; 23(1):65-75.

  43. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis [serial online] 2006 Apr. Available from: URL: http://www. cdc.gov/pcd/issues/2006/apr/05_0180.htm.

  44. Anthenelli RM. Treating patients with bipolar disorder and COPD or asthma. Suppl to Curr Psych 2005; 4:34–42.

  45. Carney CP, Jones LE. Medical comorbidity in women and men with bipolar disorders: a population-based controlled study. Psychosom Med 2006; 68: 684–691.

  46. Heffner JL, Winders-Barrett S, Anthenelli RM. Obesity and smoking. In: McElroy SL, Allison DB, Bray GA eds. Obesity and Mental Disorder. New York: Taylor &Francis, 2006: 123–144.

  47. Hayford KE, Patten CA, Rummans TA, Schroeder DR, Offord KP, Croghan IT, et al. Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. Br J Psychiatry 1999; 174:173-178.

  48. Hays JT, Hurt RD, Rigotti NA et al. Sustained release bupropion for pharmacologic relapse prevention after smoking cessation. Ann Intern Med 2001; 135:423-433.

  49. Covey L, Glassman A, Stetner F et al. A randomized trial of sertraline as a cessation aid for smokers with a history of major depression. Am J Psychiatry 2002; 159(10): 1731-1737.

  50. Graff FS, Griffin ML, Weiss RD. Predictors of dropout from group therapy among patients with bipolar and substance use disorders. Drug Alcohol Depend 2008; 94: 272-275.

  51. Grant BF, Hasin DS, Chou SP et al. Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry 2004; 61: 1107–1115.

  52. Heffner JL, Del Bello MP, Anthenelli RM et al. Cigarette smoking and its relationship to mood disorder symptoms and co-occurring alcohol and cannabis use disorders following first hospitalization for bipolar disorder. Bipolar Disord. 2012; 14 (1): 99–108.

  53. Ostacher MJ, Lebeau RT, Perlis RH et al. Cigarette smoking is associated with suicidality in bipolar disorder. Bipolar Disord. 2009; 11: 766-771.

  54. Kurtz MM, Gerraty RT. A meta-analytic investigation of neurocognitive deficits in bipolar illness: profile and effects of clinical state. Neuropsychol. 2009; 23: 551–562.

  55. Wilens TE, Biederman J, Adamson JJ et al. Further evidence of an association between adolescent bipolar disorder with smoking and substance use disorders: a controlled study. Drug Alcohol Depend. 2008; 95: 188–198.

  56. Zevin S, Benowitz NL. Drug interactions with tobacco smoking: an update. Clin Pharmacokinet. 1999; 36: 425–438.

  57. Bigos KL, Pollock BG, Coley KC et al. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol. 2008; 48: 157–165.

  58. Rostami-Hodjegan A, Amin AM, Spencer EP et al. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol. 2004; 24: 70–78.

  59. Haslemo T, Eikeseth PH, Tanum L et al. The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur J Clin Pharmacol. 2006; 62: 1049–1053.

  60. Altamura AC, Bassetti R, Bignotti S et al. Clinical variables related to suicide attempts in schizophrenic patients: a retrospective study. Schizophr Res. 2003; 60: 47-55.

  61. Gehricke J-G, Loughlin SE, Whalen CK et al. Smoking to self-medicate attentional and emotional dysfunctions. Nicotine Tobacco Res. 2007; 9: S523–S536.

  62. Lerman C, Audrain J, Tercyak K et al. Attention-deficit hyperactivity disorder (ADHD) symptoms and smoking patterns among participants in a smoking cessation program. Nicotine Tobacco Res 2001; 3: 353–359.

  63. Singh MK, Del Bello MP, Kowatch RA, Strakowski SM. Cooccurrence of bipolar and attention-deficit hyperactivity disorders in children. Bipolar Disord. 2006; 8:710–720.

  64. Williams JM, Gandhi KK, Benowitz NL. Carbamazepine but not valproate induces CYP2A6 activity in smokers with mental illness. Cancer Epidemiol Biomarkers Prev. 2010; 19: 2582–2589.

  65. Law CW, Soczynska JK, Woldeyohannes HO et al. Relation between cigarette smoking and cognitive function in euthymic individuals with bipolar disorder. Pharmacol Biochem Behav. 2009 Mar; 92(1):12-16.

  66. Leeman RF, McKee SA, Toll BA et al. Risk factors for treatment failure in smokers: relationship to alcohol use and to lifetime history of an alcohol use disorder. Nicotine Tobacco Res. 2008; 10: 1793–1809.

  67. Grant 2005 Grant BF, Stinson FS et al. Prevalence, correlates, and comorbidity of bipolar I disorder and axis I and II disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2005; 66: 1205–1215.

  68. Glassman AH, Covey LS, Dalack GW et al. Smoking cessation, clonidine, and vulnerability to nicotine among dependent smokers. Clin Pharmacol Ther. 1993; 54: 670–679.

  69. Williams JM, Gandhi KK, Steinberg ML et al. Higher nicotine and carbon monoxide levels in menthol cigarette smokers with and without schizophrenia. Nicotine Tobacco Res. 2007; 9: 873-881.

  70. Gershon Grand RB, Hwang S, Han J et al. Short-term naturalistic treatment outcomes in cigarette smokers with substance abuse and/or mental illness. J Clin Psychiatry. 2007; 68: 892-898.

  71. Fiore MC, Jaén CR, Baker trastorno bipolar et al. Clinical Practice Guideline. Treating Tobacco use Dependence: 2008 update. Rockville, MD: U. S. Department of Health and Human Services; 2008.

  72. Carreras JM, Dóniga IF, Quesada M, Sánchez B. Design and early results of proactive telephone-based smoking cessation treatment compared with face-to-face group sessions. Medicina Clínica. 2007; 128: 247-250.

  73. Schroeder SA, Morris CD. Confronting a neglected epidemic: tobacco cessation for persons with mental illness and substance abuse problems Annu. Rev. Public Health 2010; 31:16.1-16.18.

  74. Banham L, Gilbody S. Smoking cessation in severe mental illness: what works? Addiction. 2010 105: 1176-1189.

  75. Sáiz Martínez PA, García-Portilla González MP, Martínez Larrondo S et al. Tratamiento farmacológico. Psicofármacos. Adicciones 2004; 16 (Supl. 2: 275-285)

  76. Mackowick KM, Lynch MJ, Weinberger AH, George TP. Treatment of tobacco dependence in people with mental health and addictive disorders. Curr Psychiatry Rep. 2012; 14: 478-485.

  77. Clayton AH. Extended-release bupropion: an antidepressant with a broad spectrum of therapeutic activity? Expert Opin Pharmacother. 2007; 8: 457-466.

  78. Smith SS, McCarthy DE, Japuntich SJ et al. Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics. Arch Intern Med. 2009; 169: 2148–2155.

  79. Anthenelli RM, Hill KK, Ekhator NN et al. A preliminary evaluation of cigarette smoking effects on cerebrospinal fluid 5- hydroxyindolacetic acid concentrations. 7th Annual Meeting of the Society for Research on Nicotine and Tobacco, Seattle, W.A.; 2001.

  80. Leverich GS, Altshuler LL, Frye MA et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry. 2006; 163: 232-239.

  81. Dervaux A, Laqueille X. Antidepressant treatment and smoking cessation in bipolar disorder. JAMA 2009; 301: 2093.

  82. Gonzales D, Rennard SI, Nides M et al. Varenicline Phase 3 Study Group. Varenicline, an a4b2 nicotinic acetylcholine receptor partial agonist, vs. bupropion and placebo for smoking cessation: A randomized controlled trial. JAMA 2006; 296: 47–55.

  83. Gunnell D, Irvine D, Wise L , Davies C, Martin RM Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. Br Med J. 2009; 339: 3805-3808.

  84. Olano E, Minué C, Ayesta FJ. Tratamiento farmacológico de la dependencia de la nicotina: revisión de la evidencia científica y recomendaciones de la Sociedad Española de Especialistas en Tabaquismo sobre su elección e individualización. Med Clin (Barc).2011; 136 :79-83.

  85. Rigotti NA. Strategies to help a smoker who is struggling to quit. JAMA 2012; 308(15):1573-1580.

  86. Brown RA, Kahler CW, Niaura R et al. Cognitive behavioral treatment for depression in smoking cessation. J Consult Clin Psychol. 2001; 69: 471–480.

  87. Roncero C, López-Ortiz C, Barral C et al. Tratamiento concomitante de litio y metadona en un paciente bipolar: a propósito de un caso. Adicciones 2009; 21: 131-142.

  88. Chengappa K, Gershon L, Kupfer D. Lifetime prevalence of substance or alcohol abuse and dependence among subjects with bipolar I and II disorders in a voluntary registry. Bipolar Disord. 2000; 2: 191-195.

  89. Torrecillas García M, Barrueco M, Maderuelo JA et al. El abordaje del tabaquismo en atención primaria y especializada, una oportunidad real y una necesidad de salud pública. Atención Primaria 2002; 30: 197-206.




2020     |     www.medigraphic.com